Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HRTX 
Heron Therapeuti (HRTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: HRTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.75
1 Year Target Price $4.75
| 2 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.87% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 247.47M USD | Price to earnings Ratio - | 1Y Target Price 4.75 |
Price to earnings Ratio - | 1Y Target Price 4.75 | ||
Volume (30-day avg) 3 | Beta 1.25 | 52 Weeks Range 1.04 - 2.68 | Updated Date 10/21/2025 |
52 Weeks Range 1.04 - 2.68 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.62% | Operating Margin (TTM) -4.4% |
Management Effectiveness
Return on Assets (TTM) 0.34% | Return on Equity (TTM) -2408.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 374418731 | Price to Sales(TTM) 1.65 |
Enterprise Value 374418731 | Price to Sales(TTM) 1.65 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA 49.68 | Shares Outstanding 183314409 | Shares Floating 127017584 |
Shares Outstanding 183314409 | Shares Floating 127017584 | ||
Percent Insiders 0.62 | Percent Institutions 73.84 |
Upturn AI SWOT
Heron Therapeuti
Company Overview
History and Background
Heron Therapeutics, Inc. was founded in 1998. It is a commercial-stage biotechnology company focused on developing novel, best-in-class therapeutics to address unmet medical needs. Significant milestones include FDA approvals for its acute care and oncology care products.
Core Business Areas
- Acute Care: This segment focuses on developing and commercializing products that address pain and other medical conditions in acute care settings, such as post-operative pain management.
- Oncology Care: This segment focuses on developing and commercializing products that address chemotherapy-induced nausea and vomiting (CINV).
Leadership and Structure
Barry D. Quart, Pharm.D., is the Chairman and Chief Executive Officer. The company has a typical structure with departments like R&D, Commercial, Finance, and Operations.
Top Products and Market Share
Key Offerings
- Zynrelef: A non-opioid, extended-release local anesthetic approved for post-surgical pain management. Competitors include traditional opioids and other local anesthetics. Revenue for this product contribute significant amount to Heron's portfolio and have been steadily growing over the years. Market Share for Non Opioid Pain Managemen is in the early adopter stage and the overall numbers are fragmented. Heron is a leader in this space. The market is competitive including companies like Pacira BioSciences (EXPA).
- Cinvanti: An intravenous (IV) formulation of aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV). Competitors include oral aprepitant and other antiemetic medications. Heron captured a significant share of this space and is a major revenue contributor. This product is widely used in Oncology. Competitors include Teva Pharmaceutical Industries (TEVA), and Mylan (VTRS).
- Aponvie: An injectable emulsion containing aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, is indicated in adults, in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). Competitors include similar NK1 receptor antagonists administered as single agents. Market share is steadily growing with strong competition. Competitors include Tesaro (GSK) and Merck (MRK).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. Heron operates in the pain management and oncology supportive care markets, which are growing due to an aging population and advances in cancer treatment.
Positioning
Heron is positioned as an innovator in non-opioid pain management and CINV prevention. Its competitive advantages include its proprietary Biochronomer drug delivery technology and differentiated product formulations.
Total Addressable Market (TAM)
The TAM for post-operative pain management and CINV prevention is estimated to be in the billions of dollars. Heron is aiming to capture a significant share of these markets with its innovative products.
Upturn SWOT Analysis
Strengths
- Innovative drug delivery technology (Biochronomer)
- FDA-approved products addressing unmet needs
- Strong intellectual property portfolio
- Experienced management team
- Non-opioid pain management solutions
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Dependence on successful commercialization of new products
- High debt levels
- Competition from larger pharmaceutical companies
Opportunities
- Expanding product portfolio through internal development and acquisitions
- Entering new geographic markets
- Partnering with other pharmaceutical companies
- Gaining more market share with existing products
- Increase in non-opioid based surgical practices
Threats
- Competition from generic drugs
- Changes in regulatory environment
- Product liability lawsuits
- Pricing pressures from payers
- Failure to obtain regulatory approval for new products
Competitors and Market Share
Key Competitors
- Pacira BioSciences (PCRX)
- Teva Pharmaceutical Industries (TEVA)
- Merck (MRK)
Competitive Landscape
Heron's strengths include its innovative products and proprietary technology. Its weaknesses include its smaller size and limited resources compared to larger pharmaceutical companies.
Major Acquisitions
APONVIE
- Year: 2023
- Acquisition Price (USD millions): 67
- Strategic Rationale: Aponvie will fit strategically with Heron's existing portfolio of products addressing CINV in patients receiving chemotherapy.
Growth Trajectory and Initiatives
Historical Growth: Heron has experienced revenue growth in recent years, driven by the commercialization of its products.
Future Projections: Analyst estimates should be obtained from financial data providers for accurate revenue projections.
Recent Initiatives: Recent initiatives include the expansion of its sales force, the development of new product formulations, and strategic acquisitions.
Summary
Heron Therapeutics is a biotechnology company with FDA-approved products in the pain management and oncology supportive care areas. Their proprietary technology and innovative products are key strengths. However, they face competition and high R&D costs. Future growth depends on successfully commercializing new products and expanding into new markets. While revenues have been growing in the past few years, Heron needs to watch its debt and continue to expand on its product line.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Heron Therapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Heron Therapeuti
Exchange NASDAQ | Headquaters Cary, NC, United States | ||
IPO Launch date 1987-08-26 | CEO & Director Mr. Craig Alexander Collard | ||
Sector Healthcare | Industry Biotechnology | Full time employees 122 | Website https://www.herontx.com |
Full time employees 122 | Website https://www.herontx.com | ||
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.